|
|
Press Releases
| All Releases |
|---|
 |
Osiris Therapeutics Reports First Quarter 2008 Financial Results
05-09-08
19.7 KB
|
| |
COLUMBIA, Md., May 09, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today its results for the first quarter of 2008.
Highlights
-- Entered in...
|
|
Osiris and NuVasive Enter into Definitive Agreement for Osteocel(R)
05-08-08
13.9 KB
|
| |
COLUMBIA, Md., May 08, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has entered into a definitive agreement with NuVasive, Inc. (NASDAQ:NUVA) to sell Osiris' Osteocel business for up to $85 million in upfront and milestone payments. In a separate agreement worth up to an additional $52 million in revenue t...
|
|
Osiris Receives Approval for Use of Prochymal(TM) Under FDA Expanded Access Treatment Program
05-08-08
13.6 KB
|
| |
COLUMBIA, Md., May 08, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced it has been given clearance by the U.S. Food and Drug Administration (FDA) to initiate an expanded access treatment program for Prochymal, making the investigational stem cell product available to children with life-threatening Graft vs. Host Dise...
|
|
Osiris Announces First Quarter 2008 Financial Results Conference Call
05-05-08
10.1 KB
|
| |
COLUMBIA, Md., May 05, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that it will report its financial results for the quarter ended March 31, ...
|
|
Osiris Therapeutics to Present at the Lehman Brothers Healthcare Conference
03-17-08
9.4 KB
|
| |
COLUMBIA, Md., Mar 17, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and Chief Executive Officer, is sch...
|
|
Osiris Therapeutics Reports Record Fourth Quarter and Full Year 2007 Financial Results
02-28-08
21.2 KB
|
| |
COLUMBIA, Md., Feb 28, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today its results for the fourth quarter and year ended December 31, 2007.
"I...
|
|
Osiris Therapeutics Strengthens Management Team
02-27-08
10.5 KB
|
| |
COLUMBIA, Md., Feb 27, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today the addition Dr. Jeffry Lawrence, M.D. as Executive Medical Director and D...
|
|
Osiris Therapeutics to Present at the Canaccord Adams Small-Cap Orthopedics Conference
02-26-08
9.5 KB
|
| |
COLUMBIA, Md., Feb 26, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and Chief Executive Officer, is sch...
|
|
Prochymal(TM) Demonstrates Lasting Benefit in Heart Attack Patients; Osiris Receives FDA Clearance to Start Phase II Trial
02-26-08
13.0 KB
|
| |
COLUMBIA, Md., Feb 26, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that interim results at the one year time point for the Company's Phase I trial evaluating Prochymal(TM) for the treatment of heart attack patients continued to demonstrate a strong safety profile and statistically significant improvement in heart...
|
|
Osiris Announces Fourth Quarter and Full Year 2007 Financial Results Conference Call
02-25-08
10.2 KB
|
| |
COLUMBIA, Md., Feb 25, 2008 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that it will report its financial results for the fourth quarter and full ...
|
|
|
 |
Stock Information
OSIR - (NASDAQ)
$12.92
+ 0.25
|
05-12-08
11:33 AM ET
Quotes delayed at least 20 minutes. Information provided by TurboFeed.
|
|
|
|
|
Shareholder Tools
|
|
